BPL-003 (mebufotenin benzoate) vs VLS-01

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline

BPL-003 (mebufotenin benzoate)

Developed by AtaiBeckley Inc. and partners

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT05870540 · Phase 2 · completed

The core study randomized 196 participants and used a masked design with an active-placebo comparator; its primary endpoint was the clinical depression measure MADRS. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2026 · NCT05660642 (registry estimate)

Reported efficacy

Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) (4 weeks): MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025). (met)

Result source: NCT05870540

VLS-01

Developed by AtaiBeckley Inc. and partners

Phase 2 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBPL-003 (mebufotenin benzoate)VLS-01
MADRS, change (acute)-11.1 vs -5.8avs 0.3 mg comparator arm12 mg BPL-003 · wk 4.142857NCT05870540
1 other result
  • -12.1 vs -5.8 8 mg BPL-003 · wk 4.142857 · Phase 2 · primary NCT05870540
—Not reported
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

BPL-003 (mebufotenin benzoate)
-11.1 vs -5.8avs 0.3 mg comparator arm12 mg BPL-003 · wk 4.142857NCT05870540
1 other result
  • -12.1 vs -5.8 8 mg BPL-003 · wk 4.142857 · Phase 2 · primary NCT05870540
VLS-01
—Not reported

CGI-S, change (acute)

BPL-003 (mebufotenin benzoate)
—Not reported
VLS-01
—Not reported

MADRS response

BPL-003 (mebufotenin benzoate)
—Not reported
VLS-01
—Not reported

MADRS remission

BPL-003 (mebufotenin benzoate)
—Not reported
VLS-01
—Not reported

Relapse (% of patients)

BPL-003 (mebufotenin benzoate)
—Not reported
VLS-01
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

VLS-01: no structured comparison results are available for Major Depressive Disorder.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BPL-003 (mebufotenin benzoate)

MADRS -11.1 vs -5.8 0.3 mg comparator arm score @ 4.142857wk12 mg BPL-003
absolute change · score
NCT05870540 · Phase 2 · sponsor-reported, not registry data
show 1 more result
-12.1 vs -5.8 0.3 mg comparator score @ 4.142857wk8 mg BPL-003
NCT05870540 · Phase 2 · sponsor-reported, not registry data

Treatment-Resistant Depression

Shared mechanism: 5-HT2A receptor · full Treatment-Resistant Depression pipeline

BPL-003 (mebufotenin benzoate)

Developed by AtaiBeckley Inc. and partners

Phase 2 in Treatment-Resistant Depressionsmall molecule
Partial signal

NCT05870540 · Phase 2 · completed

The core study randomized 196 participants and used a masked design with an active-placebo comparator; its primary endpoint was the clinical depression measure MADRS. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2026 · NCT05660642 (registry estimate)

Reported efficacy

Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) (4 weeks): MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025). (met)

Result source: NCT05870540

VLS-01

Developed by AtaiBeckley Inc. and partners

Phase 2 in Treatment-Resistant Depressionsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Treatment-Resistant Depression

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

VLS-01: no structured comparison results are available for Treatment-Resistant Depression.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BPL-003 (mebufotenin benzoate)

MADRS -11.1 vs -5.8 0.3 mg comparator arm score @ 4.142857wk12 mg BPL-003
absolute change · score
NCT05870540 · Phase 2 · sponsor-reported, not registry data
show 1 more result
-12.1 vs -5.8 0.3 mg comparator score @ 4.142857wk8 mg BPL-003
NCT05870540 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPL-003 (mebufotenin benzoate)'s landscape · VLS-01's landscape